Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I StudyJung Min Lee, Elise C. Kohn, Dana‐Adriana Botesteanu et al.|Journal of Clinical Oncology|2017Cited by 241
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analysesAlexandra S. Zimmer, Jung Min Lee, E. Hitt Nichols et al.|Journal for ImmunoTherapy of Cancer|2019Cited by 112
<scp>HER2‐positive</scp> breast cancer brain metastasis: A new and exciting landscapeAlexandra S. Zimmer, Carey K. Anders, Amanda E.D. Van Swearingen|Cancer Reports|2020Cited by 104
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast CancerMargaret E. Gatti‐Mays, Jung Min Lee, Fatima Karzai et al.|The Oncologist|2020Cited by 59
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain MetastasesSarah Jenkins, Alexandra S. Zimmer, Wei Zhang et al.|Clinical Cancer Research|2023Cited by 23